Clinical Trials Directory

Trials / Sponsors / Neovii Biotech

Neovii Biotech

Industry · 16 registered clinical trials.

StatusTrialPhaseStarted
CompletedStudy of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia
Phase 32011-10-10
TerminatedA Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Do
Epithelial Cancer Patients
Phase 12011-02-01
CompletedSafety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
Malignant Ascites Due to Epithelial Carcinoma
Phase 22009-11-01
CompletedCASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites
Cancer, Neoplasms, Carcinoma
Phase 32008-12-01
TerminatedPhase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression
Metastatic Breast Cancer, Advanced Breast Cancer
Phase 22008-01-01
CompletedPhase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients W
Ovarian Cancer, Epithelial Ovarian Cancer
Phase 22007-11-01
CompletedPhase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Gastric Cancer, Gastric Adenocarcinoma
Phase 22007-04-01
TerminatedPhase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After
Metastatic Breast Cancer, Advanced Breast Cancer
Phase 22007-03-01
TerminatedEfficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
Renal Transplant Rejection
Phase 32006-10-01
CompletedSafety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Ovarian Cancer
Phase 22006-09-01
CompletedSafety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
Gastric Cancer, Gastric Adenocarcinoma
Phase 22006-07-01
TerminatedSafety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metasta
Breast Neoplasms, Breast Cancer
Phase 22006-07-01
CompletedStudy of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Malignant Ascites
Phase 22006-06-01
CompletedEZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis
Phase 32005-01-01
CompletedStudy in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites
Phase 2 / Phase 32004-09-01
CompletedAcute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Tr
Graft vs Host Disease
Phase 32003-02-01